Skip to content

A Study of Rapcabtagene Autoleucel in Patient With Active, Refractory Systemic Lupus Erythematosus (SLE) Patients or Lupus Nephritis (LN)

A Study of Rapcabtagene Autoleucel in Patient With Active, Refractory Systemic Lupus Erythematosus (SLE) Patients or Lupus Nephritis (LN) - CYTB323J12201

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2013240039
Enrollment
15
Registered
2024-10-15
Start date
2025-02-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active, refractory systemic lupus erythematosus (SLE) or lupus nephritis (LN)

Interventions

Experimental: rapcabtagene autoleucel

Sponsors

Yamauchi Kyosuke
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Men and women with SLE, aged >= 18 years and == 1:80 (on HEp-2 cells or an equivalent positive test), or anti-dsDNA (above the ULN); or anti-Sm (above the ULN) as determined by a central laboratory. - Active lupus nephritis without signs of significant chronicity or active systemic lupus erythematosus - SLEDAI-2K Criteria at screening: SLEDAI-2K score >= 6 points (Gladman et al 2002, Touma et al 2011), excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome". - Inadequate response at screening to at least two treatment regimens

Exclusion criteria

Exclusion criteria: - Any acute, severe lupus related-flare at screening that needs immediate treatment other than pulse GCs and/or makes the immunosuppressive washout impossible and, thus, makes the participant ineligible for CD19 CAR-T therapy - Inadequate organ function during screening and prior to randomization - History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants prior to randomization - Human immunodeficiency virus (HIV) positivity at screening. - Acute or chronic infection with hepatitis B (HBV) or hepatitis C (HCV) at screening. - Grade 2 or higher thromboembolic event in the past 4 weeks prior to screening.

Design outcomes

Primary

MeasureTime frame
Percentage of participants achieving Definition Of Remission In Systemic Lupus Erythematosus (DORIS) or clinical response at Week 24/52.

Countries

Australia, Austria, Brazil, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, UK, United States

Contacts

Public ContactKyosuke Yamauchi

Novartis Pharma. K.K.

rinshoshiken.toroku2@novartis.com+81-120-003-293

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026